Human periostin plays a multifaceted role in remodeling the extracellular matrix milieu by interacting with other proteins and itself in both a heterophilic and homophilic manner. However, the structural mechanism for its extensive interactions has remained elusive. Here, we report the crystal structures of human periostin (EMI-Fas1 I-IV ) and its Cys60Ala mutant. In combination with multi-angle light-scattering analysis and biochemical assays, the crystal structures reveal that periostin mainly exists as a dimer in solution and its homophilic interaction is mainly mediated by the EMI domain. Furthermore, Cys60 undergoes cysteinylation as confirmed by mass spectroscopy, and this site hardly affects the homophilic interaction. Also, the structures yield insights into how periostin forms heterophilic interactions with other proteins under physiological or pathological conditions.
Periostin is an extracellular matrix protein. Originally isolated from osteoblasts and preferentially found in bone tissue [1, 2] , human periostin is expressed in the connective tissues, such as cardiac valve, alveolar wall in the lung, and periodontal ligament [3] . Periostin has also been found in some pathological contexts, including infarcted myocardium, fibrosis, and cancer-associated stroma [3] . Accumulating evidence has demonstrated that periostin is highly expressed in a growing long list of cancers and closely associated with poor prognosis of some cancers [4] . As a key component in tumor microenvironment, human periostin plays a multifaceted role in promoting cancer cell proliferation, hypoxic survival, and metastasis [5] [6] [7] [8] [9] [10] . Due to high-expression in many cancers and multifaceted role in tumorigenesis, periostin has been considered as a potential target for anti-cancer therapeutics [11] . The versatile role of periostin in pathophysiological states may derive from its extensive interactions with many proteins in the extracellular milieu [3] .
As a secretory protein of around 90 kDa, human periostin is composed of an N-terminal signal peptide followed by a cysteine-rich domain (also known as EMI domain), a tandem of four repeated and conserved Fas1 domains (sequentially named Fas1 I-IV ), Abbreviations ACN, acetonitrile; AGC target, automatic gain control target; BSA, bovine serum albumin; DTT, dithiothreitol; ECM, extracellular matrix; FA, formic acid; FBS, fetal bovine serum; HBS, HEPES-buffered saline; HCD, higher energy collision induced dissociation; HEPES, N-2-hydroxyethylpiperazine-N-2-ethane sulfonic acid; HRP, horseradish peroxidase; LC, liquid chromatogram; MALS, multi-angle light scattering; MFAS, midline fasciclin; MR, molecular replacement; MS, mass spectroscopy; NEM, N-ethylmaleimide; RMSD, root-mean-square deviation; SASA, solvent accessible surface area; SDS/PAGE, sodium dodecyl sulfate polyacrylamide gel electrophoresis; TBS, Tris-buffered saline; TGFBIp, TGF--induced protein; TMB, 3, 3´, 5, 5´-Tetramethylbenzidine; Ve, elution volume. and a C-terminal variable hydrophilic region. Since its Fas1 domains are homologous to insect protein fasciclin1, periostin is assigned to the fasciclin family that mainly includes TGF-β-induced protein (TGFBIp) and midline fasciclin (MFAS) [1, 12] . The multidomain structure of periostin may constitute the basis for its functioning as a scaffold in the extracellular matrix environment, because it may bring the interacting proteins in close proximity and facilitate the assembly of extracellular matrix proteins into highly sophisticated extracellular meshwork architectures [3] . Periostin has been reported to take part in extracellular matrix remodeling by interacting with collagen, fibronectin, tenascin-C, and periostin itself in both heterophilic and homophilic manners [13, 14] .
Undoubtedly, structural characterization will help understanding periostin's multiple functions at the molecular level and designing therapeutics that may precisely modulate its functions at different pathological contexts. However, molecular and structural mechanisms for periostin's multiple interactions with itself and extracellular matrix proteins remain elusive. It has been suggested that the Fas1 domains of periostin are responsible for homophilic interaction with itself and heterophilic interaction with tenascin-C [13, 14] . As a contrast, the EMI domain of periostin has recently been reported to account for its multimerization, and mutation of Trp65 in the EMI domain of mouse periostin impaired periostin interaction with fibronectin and thus inhibited incorporation of tenascin-C into the extracellular matrix [15] . Seemingly, the role of the EMI domain in mediating homophilic interaction of periostin remains somewhat controversial.
Meanwhile, the free Cys65 in the EMI domain of human TGFBIp, a homologous protein of human periostin with 48% sequence identity, was observed to undergo cysteinylation, and this residue may form a disulfide bond linkage with collagens [16] [17] [18] . Does human periostin have the same chemical modification? How does such a modification affect periostin's homophilic and heterophilic interactions? To answer these questions may help gain insights into periostin's functionality in promoting hypoxic survival of cancer cells such as colon [8] , nonsmall-cell lung [9] , and gastric cancer cells [19] , since covalent modification at cysteine of a protein represents a prominent molecular mechanism for transforming an oxidant signal into a biological response [20] , and also, since oxygen limitation is central in controlling neovascularization, survival, and tumor spread [21] .
Here, we report the crystal structures of the wildtype and the Cys60Ala mutant of a human periostin construct containing the EMI domain and four Fas1 domains (hereafter named EMI-Fas1 I-IV ). During our preparation for this manuscript, the NMR structure of human periostin Fas1 IV domain (PDB code: 5WT7) and the crystal structure of human TGFBIp EMIFas1 I-IV (PDB code: 5NV6) have been reported [22, 23] . However, different from the two structures [22, 23] , our crystal structures, in combination with biophysical and biochemical assays, reveal that human periostin mainly exists as a dimer in solution and its homophilic interaction is mainly mediated by the EMI domain. Also, together with mass spectroscopy, our multidomain structures indicate that cysteinylation occurs at Cys60 of human periostin and this chemical modification hardly affects its homophilic interaction. In addition, our structures yield insights into how periostin forms heterophilic interactions with other extracellular matrix proteins under physiological or pathological conditions.
Materials and methods

Cloning and baculovirus generation
The proteins were expressed in the BacMam system as described previously [24] . The coding sequences of the fulllength human periostin (residues 22-836), the EMI-Fas1 I-IV (residues 22-630), and the Fas1 I-IV (residues 97-630) constructs were PCR-amplified and subcloned into a modified BacMam vector with a C-terminal 7-His tag. This vector was generously gifted by Dr Xiaolin He [25, 26] . For generating the site-directed mutants of human periostin EMI-Fas1
I-IV , Cys60Ala, Arg463Ser, and Arg463Asn/Ala465Ser, tworound overlapping PCR was performed to amplify cDNA. Following the protocol used for recombinant baculovirus generation [25] , the constructed transfer plasmids and the BacVector-3000 baculovirus DNA (EMD Biosciences, Colorado, USA) were used to co-transfect sf9 insect cells in the presence of Cellfectin II Reagent (Invitrogen, Beijing, China). Seven days post transfection, the low-titer virus stock was harvested to infect sf9 cells for amplification.
Protein expression and purification
The high-titer baculovirus stock was used to transduce HEK293S GnTl À cells [27] in DMEM/F12 medium (Invitrogen) (at 37°C and under 5% CO 2 ). Sixty-six hours post viral transduction, the supernatant was harvested by centrifugation and exchanged into TBS buffer (20 mM Tris, pH 7.5, 500 mM NaCl). The recombinant proteins were captured by Ni 2+ -NTA metal affinity resin (Invitrogen) and washed extensively with a gradient of imidazole-containing TBS buffers. After being resolved on SDS/PAGE gels stained with Coomassie Brilliant Blue G-250, the highpurity eluates were subjected to a gel-filtration column (Superdex 200 Increase, GE Healthcare, Beijing, China) pre-equilibrated and eluted with TBS buffer. The peak fractions were pooled and concentrated to 10-20 mgÁmL À1 for crystallization or other assays.
Crystallization, data collection, and processing Structure determination, refinement, and validation
The crystal structure of human periostin EMI-Fas1 I-IV was solved using the molecular replacement (MR) method by the program PHASER in PHENIX [29] and using the structure of the fourth Fas1 domain of TGFBI (PDB code: 2LTB) [30] as a search template. After multiple rounds of searching for MR solutions, the obtained model with four Fas1 domains was applied to rigid body and positional refinements in PHE-NIX. The resulted model was sequentially subjected to AutoBuild in PHENIX for building the EMI domain. The model was improved by iterative manual building in COOT [31] and refinement in PHENIX. In order to avoid MR template bias, composite omit maps were created using PHENIX between iterations of model building and refinement. During the late stage of refinement, water molecules and metal ions were automatically introduced using PHENIX or manually edited according to chemical environment. The final model validation was performed using Molprobity [32] in PHENIX.
With the structure of EMI-Fas1 I-IV as a template, the crystal structure of the Cys60Ala mutant was solved using the MR method. The subsequent refinement was performed using PHENIX and visualized using COOT. For the two structures, the side chains of Lys61 and Trp63 were not completely discerned in density map, and we did not build model for the side chain atoms of Trp63 except its C b atom.
Data collection and refinement statistics for the two structures are summarized in Table 1 .
Multiple-sequence alignment and structure analysis
Structure-based sequence alignment was executed using ClustalW [33] and annotated using ESPRIPT [34] . For domain-domain or protein-protein interaction analysis, contacting residues and buried solvent accessible areas on the interface were calculated using CNS [35] . The probe radius was set as 1.4 A.
Multi-angle light scattering
Prior to multi-angle light-scattering (MALS) assay, proteins were concentrated to 1 mgÁmL À1 and applied to centrifugation at 15 000 g for 10 min. MALS experiments were performed during size-exclusion chromatography on a WTC-015S5 (Wyatt Technology, Beijing, China) with on-line static light-scattering (DAWN HELEOS II, Wyatt Technology) and differential refractive index (Optilab T-rEX, Wyatt Technology) detectors. The sample flow rate was set as 0.4 mLÁmin À1 . Data were analyzed using the ASTRA software package (Wyatt Technology).
Liquid chromatogram-MS/MS
For analyzing the chemical modification at Cys60, the crystals of human periostin EMI-Fas1 I-IV were collected, dissolved in water with 6 M urea, and applied to trypsin digestion for mass spectrometry analysis. For complete disulfide bond assignment, recombinant human periostin EMI-Fas1 I-IV was dissolved in 100 mM Tris buffer (pH 6.5) supplemented with 2 mM N-ethylmaleimide (NEM), an organic compound which is critical in minimizing disulfide scrambling during MS experiment [36] . Please see supporting information for experimental procedures in detail.
Homophilic interaction assay
The 96-well plates were coated with 10 lgÁmL À1 periostin EMI-Fas1 I-IV at 37°C for 2 h and blocked with TBST buffer (20 mM Tris-HCl, pH 7.5, 0.5 M NaCl, 0.05% Tween-20) supplemented with 3% BSA at 37°C for 1 h. For generating biotinylated samples, proteins in HBS were incubated with biotin (Bioss, Beijing, China) at a molar ratio of 1 : 20 at 37°C for 2 h, and then buffer-exchanged to the binding buffer (TBST containing 1% BSA). The indicated concentrations of biotinylated periostin EMIFas1
I-IV , Arg463Ser mutant, Arg463Asn/Ala465Ser mutant, or BSA were added to the plates and incubated overnight at 4°C. After each well was washed thrice using TBST, streptavidin-conjugated horseradish peroxidase (HRP) (Bioss) was added and incubated at 37°C. One hour later, TMB solution was added for color development reaction. After 10 min, H 2 SO 4 was added to quench the reaction, and the optical absorbance at 450 nm (OD 450 ) was measured on a microplate photometer (Multiskan Go, Thermo). The experiments were repeated three times, and data were represented as mean AE standard error of the mean (error bars).
Results
Human periostin mainly exists as a dimer in solution
For gaining biochemical and structural insights into homophilic interaction of human periostin, we expressed and purified the full-length periostin (residues 22-836) and a short construct, EMI-Fas1 I-IV , with the C-terminal variable domain deleted (Fig. 1A) . The elution volume (Ve) of the two constructs on a Superdex-200 gel-filtration column was 11.7 mL (fulllength periostin) and 13.1 mL (EMI-Fas1 I-IV ), respectively (Fig. 1B) , which implicates that both of them may likely exist as an oligomer in solution according to the molecular weight standards (Fig. S1 ). In order to precisely measure their molecular masses in solution, we applied them to gel-filtration chromatography-coupled MALS analysis. As demonstrated in Fig. 1C ,D, the apparent molecular mass of the fulllength periostin in solution was 1.695 9 10 5 AE 449 Da (Fig. 1C) , while that of the EMI-Fas1 I-IV was 1.462 9 10 5 AE 497 Da (Fig. 1D) . Both of the two measured values are approximately two times of the calculated molecular mass of the full-length periostin (90.96 kDa) and of the EMI-Fas1 I-IV construct (67.62 kDa), indicating that the two constructs both exist as a dimer in solution. Since the C-terminal variable domain is unstructured, we focused on the EMIFas1 I-IV construct which is enough to cover homophilic interaction of periostin.
Overall structure of human periostin EMI-Fas1
I-IV
Using the MR method, we determined the crystal structure of human periostin EMI-Fas1 I-IV ( Fig. 2A) Table S2 .
constitute a stable triangle-like module ( Fig. 2A) . Besides Cys69-Cys333, other four disulfide bonds, Cys44-Cys80, Cys79-Cys92, Cys208-Cys311, and Cys467-Cys472, were all clearly discernible in difference density map and convinced using mass spectrometry ( Fig. S2A-H) .
As revealed by DALI [37] searching for structural homologs, each Fas1 domain of human periostin adopts a mixed a + b fold similar to that of human TGFBIp [30] , insect cell adhesion molecule fasciclin 1 (PDB code: 1O70) [38] , MPB70 (PDB code: 1NYO) [39] , and the NDH-1 complex subunit CupS from Thermosynechococcus elongatus (PDB code: 2MXA) [40] (Fig. S3A-C) . The four Fas1 domains of human periostin can be mutually superimposed well due to their relatively high sequence similarity, and the 'pearls-on-a-string' conformation of the four Fas1 domains is maintained by exquisite domain-domain interactions (Fig. S3D-G and Table S1 ). The periostin Fas1 I /Fas1 II and Fas1 III /Fas1 IV pairs can be aligned together, which further supports that the Fas1 domains are prone to exist in a pairwise way [38] (Fig. S3H) . Interestingly, different from their homologous structures, the four Fas1 domains of periostin share a unique structural motif that Mg 2+ lies at the junction of helices aB and aD and is coordinated with the side chain amide oxygen of an asparagine and the carbonyl oxygen of a proline (Fig. S3I-L) . Both the asparagine and proline residues are located in the linker between bA and aD, and absolutely conserved in the four Fas1 domains of human periostin. Another intriguing point is that Mg 2+ is close to a relatively conserved aromatic residue (Trp142, Phe279, Phe413, and Phe541 in four domains from Fas1 I to Fas1 IV ) within a distance less than 4
A. Such a conserved structural motif would facilitate enhancing stability of the four Fas1 domains and promoting them to fold into a highly similar topology. However, functional significance of Mg 2+ is still unknown. Based on the Fas1 I-II domains, the overall structure of human TGFBIp EMI-Fas1 I-IV (PDB code: 5NV6) can be aligned well with our multiple-domain periostin structure. However, the Fas1 III /Fas1 IV pair of TGFBIp underwent a~15°rotation relating to that of periostin (Fig. 2B) . Meanwhile, the EMI domain has a large positional deviation (Fig. 2B) . Indeed, the threedimensional structure of periostin EMI is considerably distinct from that of TGFBIp EMI, although they share the same fold (Fig. 2C) . The EMI domain of periostin adopts a total b structure that features two orthogonal b-sheets arranged into two lobes (Fig. S4A,B) . The central lobe is characterized with a right-handed crossover loop, while the capping lobe features an Ω-like loop (called omega loop) (Figs 2A  and S4 ). Likely due to intrinsic flexibility, the crossover loop is partially discerned in the 2F o -F c density map contoured at 0.8 r (Fig. S4C,D) . In contrast, a modification at the side chain of Cys60 could be unambiguously seen in the density map (Fig. 2D) . For determining chemical nature of the Cys60 adduct, the crystals of human periostin EMI-Fas1 I-IV were subjected to LC-MS/MS assays. The precursor ion fragment had an m/z (mass-to-charge) value of 434.1740, corresponding to an observed molecular mass of 866.3307 Da, which is close to the calculated mass of 866.3275 Da. Compared with the molecular mass of the unmodified counterpart, the molecular mass increment of 119 Da for the precursor fragment indicates that cysteinylation occurs at the site of Cys60 (Fig. 2E and Table S2 ).
Structural basis of periostin dimerization
Structural basis of periostin dimerization may be deduced from crystal packing analysis of human periostin EMI-Fas1 I-IV domains. In the crystal, each periostin molecule is packed by five crystallographic symmetry-related molecules within the distance range of 4 A (Fig. S5 ). As shown in Fig. 3A , one periostin molecule interacts with a crystallographic two-fold axis-related molecule in a side-by-side fashion, and assemblies into a boat-like dimer. The dimer interface buries a total of 3210 A 2 solvent accessible surface area (SASA), which is the largest buried area among symmetry mates (Fig. 3A) .
The interface of the periostin dimer can be divided into two sites, with each located in one end of the 'boat' (Fig. 3A) . A close-up view of each site reveals that the EMI domain and Fas1 I domains of one periostin protomer mainly interacts with the Fas1 IV and Fas1 III domains of the other protomer, respectively. However, no direct interactions are observed between the EMI domains in the dimer. In one end of the dimer, the capping lobe of the EMI domain (residues 80-97) interacts with the bD-bE loop of the Fas1 III domain and the bC strand of the Fas1 IV domain, with 750 A 2 SASA buried (Fig. 3B) . Arg463 from the Fas1 III bD-bE loop extends its side chain into the junction of the EMI and Fas1 I domain in the other periostin molecule, forming a hydrogen bond with the main chain oxygen of Leu96. The side chains of Tyr83 and Glu578 are hydrogen bonded together. Remarkably, the main chain oxygen and nitrogen of Ala94 and Val95 in the EMI domain form three hydrogen bonds with Thr582 and Ile584 main chain atoms (Fig. 3C ). In total, there are five hydrogen bonds governing the EMI/Fas1 IV interactions in the dimer (Fig. 3C) . Besides, the residues Try83, Met86, Pro93, Ala94, Val95, and Pro97 of the EMI domain from one periostin monomer form multiple van der Waals interactions with the other monomer, further stabilizing the EMI/Fas1 IV interactions (Table S3 ). The Fas1
III interface in the dimer mainly includes residues 441-445 of the Fas1 III domain, which form a bunch of van der Waals contacts with the Fas1 I domain. In this interface, only three hydrogen bonds are observed (Fig. 3D) . Likely due to less hydrogen bonds involved, the Fas1 I /Fas1 III interactions contribute less driving force to periostin dimerization than do the EMI/Fas1 IV interactions. This implies that the EMI domain would be crucial for human periostin dimerization.
Dimerization of periostin is mediated by the EMI domain
In the absence of the EMI domain, the four Fas1 domains (Fas1 I-IV ) of human periostin still expressed well and presented a sharp peak in the gel-filtration chromatography (Fig. 4A) , suggesting that the four Fas1 domains can exist as an independent, stable module. The Ve of the Fas1 I-IV construct was larger than that of the EMI-Fas1 I-IV construct by 1.3 mL (14.4 mL versus 13.1 mL), indicating that the two constructs have a molecular mass difference of~75 kDa, far larger than the molecular mass of the EMI domain ( Figs 4A and S1 ). This implicates that the two constructs would likely have different oligomerization states. As measured by MALS analysis, the apparent 4 AE 300 Da, close to its theoretical molecular mass (59.06 kDa) (Fig. 4B) , which confirms that the Fas1 I-IV construct is a monomer in solution. Comparing the oligomerization states of EMI-Fas1 I-IV and Fas1
I-IV , we may conclude that the EMI domain is a determinant factor for periostin dimerization.
Checking the periostin dimer interface with scrutiny, we found that Arg463 has the most extensive interactions with other residues, especially with the residues in the EMI domain from the other monomer (Table S3) . Besides the hydrogen bond involved by Leu96, Arg463 engages in multiple van der Waals interactions with Tyr83, Val95, Leu96, and Pro97 from the EMI domain and Ile98 and Ile217 from the Fas1 I domain (Fig. 4C) . We prepared the Arg463Ser (R463S) mutant of human periostin EMI-Fas1 I-IV using the same protocol as used for the wild-type. The Ve of the R463S mutant was slightly larger than that of the EMI-Fas1 I-IV construct by 0.2 mL (13.3 mL versus 13.1 mL) (Fig. S6A) . The apparent molecular mass, measured by MALS assay, was 1.198 9 10 5 AE 308 Da, which is smaller than that of the native EMI-Fas1 I-IV (Fig. S6B) . Furthermore, exploiting a 'glycan wedge' strategy that we have recently used for SALM5 monomerization [41] , we introduced a double mutation of Arg463Asn/Ala465-Ser (R463N/A465S) to the dimer interface. The Ve of the R463N/A465S mutant was 14.7 mL (Fig. S6C ) and the apparent molecular mass measured by MALS assay was 7.811 9 10 4 AE 1001 Da, close to the calculated molecular mass of the N-linked glycosylated R463N/A465S mutant (68.81 kD) (Fig. S6D) , indicating that the R463N/A465S mutant mainly exists as a monomer in solution. Furthermore, in homophilic interaction assay, the binding abilities of the biotinylated Arg463Ser and R463N/A465S mutants are both weaker than that of native counterpart (Figs 4D,  S6E ). These results show that the double mutation of R463N/A465S disrupted the dimeric interface and the Arg463 site is critical for periostin dimerization.
Cys60Ala mutation hardly affected periostin dimerization
In order to obtain insights into how cysteinylation at Cys60 affects periostin dimerization, we prepared the Cys60Ala mutant of human periostin EMI-Fas1 I-IV . As shown in Fig. 5A , this mutant expressed well and crystallized into high-quality crystals that belonged to the same space group as the wild-type (Table 1) . MALS analysis indicated that the Cys60Ala mutant is dimeric in solution, with an apparent molecular mass close to that of native counterpart (Fig. 5B) . Difference density maps around the position of residue 60 clearly show that Cys60Ala mutation was successfully achieved (Fig. 5C ). Overlaying the structures of the Cys60Ala mutant and the wild-type led to a low RMSD of 0. 22 A for 558 paired C a atoms, indicating that Cys60Ala mutation did not alter the overall structure of periostin (Fig. 5D) . However, the crossover loop underwent a considerable conformational variation with the C a atom of residue 60 moving by 1.54 A and residues 61-63 by longer distances (Fig. 5D ). Except for this conformational change in the crossover loop, the mutant dimer may be structurally overlaid well with the wild-type (Fig. 5E) . Therefore, it is conclusive that mutation of Cys60 to alanine did not change the dimerization mode of periostin.
Discussion
In this paper, we presented a multiple-domain structure of human periostin that packed into a dimer and underwent cysteinylation at Cys60. The recently published human TGFBIp structure (PDB code: 5NV6) [23] can be superimposed into the periostin crystal structure (Fig. 2B) , likely due to relatively high sequence conservation (Fig. S7) . However, human TGFBIp was monomeric in crystal [23] and did not see cysteinylation at Cys65 (equivalent to Cys60 of human periostin) that has been previously reported [16] . As mentioned above, both the Fas1 III /Fas1
IV pair and the EMI domain of TGFBIp has a large movement relative to periostin (Fig. 2B) , which means that TGFBIp could not pack into a periostin-like dimer due to steric hindrance. On one hand, structural variation between TGFBIp and periostin likely supports that the two proteins, like 'two peas in one pod', have different molecular behaviors and functions although they are homologous [42] . However, combined with biophysical and biochemical assays, structural novelties of human periostin may provide new insights into how periostin performs homophilic and heterophilic interactions in the extracellular matrix environment.
In order to gain insights into homophilic interaction of human periostin, we first characterized oligomerization state of the full-length periostin and the EMIFas1 I-IV construct in solution. Size-exclusion chromatography and MALS analysis consistently showed that periostin mainly exists as a dimer in solution and that the EMI and Fas1 domains are enough to underpin homophilic interaction of periostin (Fig. 1) . A crystallographic two-fold axis related dimer of human periostin EMI-Fas1 I-IV construct buried a large SASA (~3210 A   2 ) that sufficiently implicates a biological unit. In the dimer interface, the EMI domain from one periostin molecule forms extensive interactions with the Fas1 domains from the other molecule. Deletion of the EMI domain resulted in dissociation of the periostin dimer (Fig. 4B) , which is consistent with the previous report that 'the EMI domain is responsible for the multimerization of periostin' [15] . Mutation of Arg463 on the dimer interface not only decreased the apparent molecular mass of EMI-Fas1 I-IV but also impaired homophilic interaction of periostin ( Figs 4D and S6) . Therefore, this crystallographic dimer presents a biological unit that may govern homophilic interaction of periostin in extracellular matrix remodeling [13, 14] . Meanwhile, homophilic interaction of periostin is mainly mediated by the EMI domain.
Resorting to crystallography and mass spectroscopy, we confirmed that recombinant human periostin underwent cysteinylation at Cys60 in the EMI domain (Fig. 2C,D) . To our best knowledge, it is first time to observe cysteinylation in periostin and provide structural evidence for cysteinylation in the EMI family of proteins (including TGFBIp). Likely similar to the case of human TGFBIp Cys65 [16] [17] [18] , cysteinylation at Cys60 of human periostin would mediate its heterophilic interaction with the extracellular matrix proteins. In order to obtain insights into whether cysteinylation affects homophilic interaction of human periostin, we examined the Cys60Ala mutant through structural and biophysical characterizations. As implicated in Fig. 5 , cysteinylation at Cys60 of periostin would not alter its homophilic interaction.
In general, covalent modification at cysteine of a protein represents a prominent molecular mechanism for transforming an oxidant signal into a biological response [20] . Meanwhile, oxygen limitation is known to be central in controlling neovascularization, survival, and tumor metastasis [21] . Therefore, we propose that a free and oxidizable Cys60 of periostin might serve as an oxygen sensor to activate downstream signaling and maintain its function in promoting hypoxic survival of cancer cells [8, 9, 19] . The aromatic residues Trp63, Tyr64, and Tyr77, within the distance range of 4 A around Cys60 (Fig. S8A ), might get involved in proton-coupled electron transfer during such a redox process, similar to the cases of natural and biomimetic systems [43, 44] . During this process, human periostin would consistently act as a dimer, since mutation of Cys60 to Ala did not alter the dimerization mode of periostin (Fig. 5) . However, further investigation in vivo will be needed to determine whether cysteinylation at Cys60 mediates human periostin functioning in hypoxic survival promotion. In addition, the structure of cysteinylated periostin dimer may also yield insights into how periostin exerts its multiple roles via heterophilic interactions with other proteins. The periostin dimer resembles a hollow boat with the cysteinylation site located in the inner concave side, and the inner and bottom surfaces of the 'boat' are, respectively, overwhelmed by positively and negatively charged patches (Fig. S8B-D) . The EMI domain of periostin has been documented to interact with fibronectin [15] , TGFBIp [45] , collagen bundles, and other extracellular matrix (ECM) proteins in heterophilic manners [14, 46, 47] . Residue Trp65 in mouse periostin EMI domain is essential for its interaction with fibronectin [15] , while the residue Cys65 in human TGFBIp EMI domain may covalently link via a reducible disulfide bond to collagen [17] . The two residues are conserved in the fasciclin and EMILIN [48] families and, respectively, correspond to Trp63 and Cys60 of human periostin EMI domain (Fig. S8F,G) . Thus, we propose that ECM proteins, such as fibronectin and collagen, might dock to the concave side of the dimer where the EMI domain inhabits. Meanwhile, the four Fas1 domains of periostin may bind to tenascin [15] , BMP-1 [49] , CCN3 [50] , and integrin [51] . Noteworthy to mention, monoclonal antibodies recognizing a region covering residues 136-151 in the Fas1 domain may inhibit integrin-mediated cell migration [51] . This region is negatively charged on each side of the boat-like periostin dimer (Fig. S8B,E) , which would likely facilitate its coordination to the metal ion center of integrin [52] . In addition, both fibronectin and TGFBIp may bind to collagen [15, 53] . Therefore, as proposed in Fig. 6 , the periostin dimer may likely function as a scaffold to bring interacting proteins in close proximity and facilitate the assembly of a complicated meshwork architecture in the extracellular matrix environment [3] .
Conclusions
We have determined crystal structures of human periostin EMI-Fas1 I-IV and its Cys60Ala mutant. Together with biochemical and biophysical assays, the two structures reveal that human periostin exists as a dimer in solution and homophilic interaction of periostin is mainly mediated by the EMI domain. Using crystallography and mass spectroscopy, we have for the first time observed cysteinylation at Cys60 of human periostin and found that cysteinylation does not affect human periostin dimerization. In the future, in vivo functional investigations will be needed to show how periostin orchestrates dimerization, cysteinylation, and heterophilic interaction in physiological or pathological contexts. 
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